Head and neck cancer - Part 1: Epidemiology, presentation, and prevention by Mehanna H et al.
Newcastle University e-prints  
Date deposited:  16 October 2012 
Version of file:  Published 
Peer Review Status: Peer reviewed 
Citation for item: 
Mehanna H, Paleri V, West C, Nutting C. Head and neck cancer - Part 1: Epidemiology, presentation, 
and prevention. BMJ 2010, 341(7774), 663-666. 
Further information on publisher website: 
http://www.bmj.com  
Publisher’s copyright statement: 
The definitive version of this article is published by BMJ Group, 2010 and is available at: 
http://dx.doi.org/10.1136/bmj.c4684 
Always use the definitive version when citing.   
Use Policy: 
The full-text may be used and/or reproduced and given to third parties in any format or medium, 
without prior permission or charge, for personal research or study, educational, or not for profit 
purposes provided that: 
 A full bibliographic reference is made to the original source 
 A link is made to the metadata record in Newcastle E-prints 
 The full text is not changed in any way. 
The full-text must not be sold in any format or medium without the formal permission of the 
copyright holders. 
 
 Robinson Library, University of Newcastle upon Tyne, Newcastle upon Tyne.  
NE1 7RU.  Tel. 0191 222 6000 
BMJ | 25 SEPTEMBER 2010 | VOLUME 341       663
CLINICAL REVIEWFor the full versions of these articles see bmj.com
1Institute of Head and Neck Studies 
and Education, University Hospitals 
Coventry, Coventry CV2 2DX
2Otolaryngology-Head and Neck 
Surgery, Newcastle upon Tyne 
Hospitals NHS Trust, Newcastle 
upon Tyne
3University of Manchester, 
Manchester
4Head and Neck Unit, Royal 
Marsden NHS Foundation Trust, 
London
Correspondence to: H Mehanna 
hishammehanna@aol.com
Cite this as: BMJ 2010;341:c4684 
doi: 10.1136/bmj.c4684
Head and neck cancer—Part 1:  
Epidemiology, presentation, and prevention
H Mehanna,1 V Paleri,2 C M L West,3 C Nutting4
Head and neck cancers include cancers of the upper aero-
digestive tract (including the oral cavity, nasopharynx, 
oropharynx, hypopharynx, and larynx), the paranasal 
sinuses, and the salivary glands. Cancers at different 
sites have different courses and variable histopathologi-
cal types, although squamous cell carcinoma is by far the 
most common. The anatomical sites affected are important 
for functions such as speech, swallowing, taste, and smell, 
so the cancers and their treatments may have considerable 
functional sequelae with subsequent impairment of quality 
of life. Decisions about treatment are usually complex, and 
they must balance efficacy of treatment and likelihood of 
survival, with potential functional and quality of life out-
comes. Patients and their carers need considerable support 
during and after treatment.
In this first part of a two article series, we review the 
common presentations of head and neck cancer. We also 
discuss common investigations and new diagnostic tech-
niques, as well as briefly touching on screening and preven-
tion. In this review, we have used evidence from national 
guidelines, randomised trials, and level II-III studies. We 
have limited our discussions to squamous cell carcinoma 
of the head and neck, which constitutes more than 85% of 
head and neck cancers.
How common is head and neck cancer and who gets it?
Cancer of the mouth and oropharynx is the 10th most com-
mon cancer worldwide, but it is the seventh most common 
cause of cancer induced mortality.1
In 2002, the World Health Organization estimated that 
there were 600 000 new cases of head and neck cancer and 
300 000 deaths each year worldwide, with the most com-
mon sites being the oral cavity (389 000 cases a year), the 
larynx (160 000), and the pharynx (65 000).2 The male to 
female ratio reported by large scale epidemiological stud-
ies and national cancer registries varies from 2:1 to 15:1 
depending on the site of disease.w1 The incidence of cancers 
of the head and neck increases with age. In Europe, 98% 
and 50% of patients diagnosed are over 40 and 60 years 
of age, respectively.w2
What regions have the highest incidence?
A high incidence of head and neck cancer is seen in the 
Indian subcontinent, Australia, France, Brazil, and 
Southern Africa (table). Nasopharyngeal cancer is largely 
restricted to southern China. The incidence of oral, laryn-
geal, and other smoking related cancers is declining in 
North America and western Europe, primarily because of 
decreased exposure to carcinogens, especially tobacco.2 
In contrast, because of the 40 year temporal gap between 
changes in population tobacco use and its epidemiological 
effects, the worst of the tobacco epidemic has yet to mate-
rialise in developing countries. WHO projections estimate 
worldwide mortality figures from mouth and oropharyn-
geal cancer in 2008 to be 371 000. This is projected to rise 
to 595 000 in 2030 because of a predicted rise in mortality 
in South East Asia (182 000 in 2008 to 324 000 in 2030). 
SUMMARY POINTS
The incidence of head and neck cancer is relatively low in developed countries and 
highest in South East Asia
The main risk factors are smoking and heavy alcohol consumption
Incidence of human papillomavirus related oropharyngeal carcinoma is rising rapidly 
in developed countries and is easily missed. It has a different presentation and better 
prognosis than other head and neck cancers
Patients with head and neck cancer often present with hoarseness, throat pain, tongue 
ulcers, or a painless neck lump, and symptoms for longer than three weeks’ duration 
should prompt urgent referral
No strong evidence supports visual examination or other screening methods in the 
general population
Any of the following lasting for more than 
three weeks
Symptoms
Sore throat
Hoarseness
Stridor
Difficulty in swallowing
Lump in neck
Unilateral ear pain
Signs
Red or white patch in the mouth
Oral ulceration, swelling, or loose tooth
Lateral neck mass
Rapidly growing thyroid mass
Cranial nerve palsy
Orbital mass
Unilateral ear effusion
Box 1 | “Red flag” symptoms and signs of head and neck cancer12
SOURCES AND SELECTION CRITERIA
We used the terms “head and neck”, “larynx”, “oral”, and 
“oropharynx”—with each limited by “cancer”, “diagnosis”, 
and “treatment” separately—to search the Medline, Embase, 
PubMed, Cochrane, CINAHL, and AMED databases. We also 
used them to cross check national guidelines, reference lists, 
textbooks, and personal reference lists. We assessed over 
1000 identified abstracts for relevance.
664   BMJ | 25 SEPTEMBER 2010 | VOLUME 341
CLINICAL REVIEW
Modest rises are predicted in Africa, the Americas, and the 
Middle East, whereas mortality in Europe is expected to 
remain stable.3
Several retrospective analyses of samples collected from 
patients recruited in randomised trials, as well as retrospec-
tive patient series, have shown recent changes in epidemiol-
ogy and pathogenesis of head and neck cancers related to 
the human papillomavirus (HPV), especially oropharyngeal 
carcinoma. A rapid rise in HPV related oropharyngeal can-
cers in particular has been shown in epidemiological studies 
from the developed world.4 For example, the United King-
dom has seen a doubling in the incidence of oropharyngeal 
cancer (from 1/100 000 population to 2.3/100 000) in just 
over a decade.5 A recent retrospective study showed a pro-
gressive proportional increase in the detection of HPV in 
oropharyngeal squamous cell carcinomas in Stockholm over 
the past three decades: 23% in the 1970s, 29% in 1980s, 
57% in 1990s, 68% between 2000 and 2002, 77% between 
2003 and 2005, and 93% between 2006 and 2007.6 Other 
prospective studies, such as ones from the United States, 
have also reported proportional increases.
What are the risk factors for head and neck cancer?
Tobacco and alcohol
The major risk factors are tobacco (smoking and smokeless 
products such as betel quid) and alcohol. They account for 
about 75% of cases, and their effects are multiplicative when 
combined.7 w3 Smoking is more strongly associated with 
laryngeal cancer and alcohol consumption with cancers of 
the pharynx and oral cavity.w4 Pooled analyses of 15 case-
control studies showed that non-smokers who have three or 
more alcoholic drinks (beer or spirits) a day have double the 
risk of developing the disease compared with non-drinkers 
(odds ratio 2.04, 95% confidence interval 1.29 to 3.21).8  9
Genetic factors
Most people who smoke and drink do not develop head and 
neck cancer, however, and a genetic predisposition has been 
shown to be important. The International Head And Neck 
Cancer Epidemiology Consortium (INHANCE) carried out 
pooled analyses of epidemiological studies that examined 
risks associated with the disease.7 This work confirmed the 
role of genetic predisposition that had been suggested by 
small studies. A family history of head and neck cancer 
in a first degree relative is associated with a 1.7-fold (1.2 
to 2.3) increased risk of developing the disease.7 Genetic 
polymorphisms in genes encoding enzymes involved in the 
metabolism of tobacco and alcohol have been linked with an 
increased risk of the disease. For example, a meta-analysis 
of 30 studies showed that a polymorphism in GSTM1, which 
encodes a protein involved in the metabolism of xenobiot-
ics (glutathione S transferase), was associated with a 1.23 
(1.06 to 1.42) increased risk of developing head and neck 
cancer.w5
Viral infection
Viral infection is a recognised risk factor for cancer of the 
head and neck. The association between Epstein-Barr virus 
infection and the development of nasopharyngeal cancer 
was first recognised in 1966.w6 More recently, HPV has 
attracted attention.4 Recent observational studies have found 
that this virus is a strong risk factor for the development of 
head and neck cancer, especially oropharyngeal cancer (63, 
14 to 480), and they suggest that HPV infection—especially 
infection with HPV subtype 16 (HPV-16)—is an aetiological 
factor.10 w7 The disease is thought to be sexually transmit-
ted. A pooled analysis of eight multinational observational 
studies that compared 5642 cases of head and neck cancer 
with 6069 controls found that the risk of developing oropha-
ryngeal carcinoma was associated with a history of six or 
more lifetime sexual partners (1.25, 1.01 to 1.54), four or 
more lifetime oral sex partners (3.36, 1.32 to 8.53), and—for 
men—an earlier age at first sexual intercourse (2.36, 1.37 
to 5.05).11
HPV related oropharyngeal carcinoma is a distinct disease 
entity. Patients are younger (usually 40-50 years old), often 
do not report the usual risk factors of smoking or high alco-
hol intake, and often present with a small primary tumour 
and large neck nodes. This may lead to delayed diagnosis.
Other risk factors
Other risk factors identified from pooled analyses of case-
control studies include sex (men are more likely to have 
head and neck cancer than women),7 a long duration of 
passive smoking (odds ratio for >15 years at home: 1.60, 
1.12 to 2.28),7 low body mass index (odds ratio for body 
mass index 18: 2.13, 1.75 to 2.58),w8 and sexual behaviour 
(for example, odds ratio for cancer of the base of tongue in 
men with a history of same sex sexual contact: 8.89, 2.14 
to 36.8).11 Some evidence points to a role of occupational 
exposure, poor dental hygiene, and dietary factors, such 
as low fruit and vegetable intake.w9
How does head and neck cancer present?
Patients with head and neck cancers present with a variety 
of symptoms, depending on the function of the site where 
Data for head and neck cancers in 2004 in WHO regions* 
Africa
The 
Americas†
Eastern 
Mediterranean Europe
South East 
Asia
Western 
Pacific
Population 737 536 874 380 519 688 883 311 1 671 904 1 738 457
Incidence 30 38 29 72 195 74
Mortality 22 25 22 51 158 56
*Numbers should be multiplied by 1000.
†North America, South America, and Canada. 
Box 2 | Presentations where cancer might easily be missed
Persistently enlarged neck nodes in younger patients (30-50 years)
These are often human papillomavirus related tumours. Patients often do not have the usual 
risk factors for head and neck cancer—they are often non-smokers and do not drink alcohol 
heavily. Tumours are often small or occult within normal looking tonsils. Because of the 
patient’s young age, absence of risk factors, and unusual presentation, the problem might 
be confused with benign reactive nodal enlargement and the diagnosis delayed.
Persistent unilateral otalgia with no signs of ear infection in patients over 30 
Patients with this problem should also be considered for early referral to a head and neck 
surgeon who can do a full examination of the upper aerodigestive tract with a flexible 
nasolaryngoscope to exclude pharyngeal and postnasal space tumours.
Recent onset wheeze in a patient over 40, usually a heavy smoker 
The “wheeze” is in fact a mild biphasic stridor mistaken for wheeze and the patient, who 
may also have breathlessness, may be misdiagnosed as having sequelae of chronic 
obstructive airway disease or late onset asthma and may be treated as such. This 
presentation, however, may be that of a slow growing laryngeal carcinoma. Clinicians should 
consider this diagnosis in patients with late onset wheeze or asthma that does not respond 
to drugs in patients who smoke or give a history of heavy alcohol intake.
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they originate. Laryngeal cancers commonly present with 
hoarseness, whereas pharyngeal cancers often present 
late with dysphagia or sore throat. Many often present 
with a painless neck node. Patients with head and neck 
cancer can present with non-specific symptoms or symp-
toms commonly associated with benign conditions, how-
ever, such as sore throat or ear pain.w10 Box 1 lists “red flag 
symptoms” that practice guidelines consider to warrant 
urgent referral and consultation with a specialist head 
and neck clinician. UK guidelines specify that urgent 
referral should mean that patients are seen within two 
weeks.12 Head and neck centres often run a dedicated 
clinic—a neck lump clinic—to diagnose such patients. Box 
2 describes unusual clinical scenarios in which clinicians 
may miss a diagnosis of cancer.
How are suspicious lesions investigated?
A recent BMJ clinical review discussed the investigation 
of oral lesions in detail.13 Examination of any lesion of 
the head or neck should include palpation of the entire 
neck for lymph nodes, and examination of the scalp and 
the whole oral cavity, including tongue, floor of mouth, 
buccal mucosa, and tonsils. Dentures should be removed 
before examination. The nose and ears should also be 
examined, especially if no other abnormalities are found. 
Flexible nasolaryngoscopy allows proper examination of 
the nasal cavities, postnasal space, base of the tongue, 
larynx, and hypopharynx. Box 3 summarises the investi-
gations that are performed in specialist care. 
Diagnosis of the cancer is confirmed on histology of the 
biopsy from the primary site. The new technique of fusion 
positron emission tomography-computerised tomography 
has become one of the most important diagnostic tools 
for head and neck cancers. It combines normal computed 
tomography scanning with functional imaging using 18F-
fluorodeoxyglucose (18F-FDG), which is taken up prefer-
entially by cells with high metabolic activity, especially 
cancer cells (fig). This technique can therefore help iden-
tify occult primary tumours, which are relatively common 
and not detected by examination and conventional imag-
ing. The technique may also have a role in the assess-
ment of persistent nodal disease after treatment, and in 
the monitoring and follow-up of patients with head and 
neck cancer in the longer term, but sufficient evidence to 
support this is not yet available.15
To prove that a tumour is caused by HPV, virus specific 
DNA must be identified within the tumour and it must 
be shown that it has undergone transcription. HPV DNA 
can be demonstrated by polymerase chain reaction or in 
situ hybridisation. Transcription can be demonstrated by 
using immunohistochemistry to identify expression of 
p16, a downstream product of HPV DNA transcription.16
Can we screen for head and neck cancer?
Data are available for oral cancer screening only. It is 
unclear whether treating premalignant lesions can pre-
vent the occurrence of invasive cancer.w11 A Cochrane 
review of randomised controlled trials of screening for 
oral cancer or precursor oral lesions found no strong evi-
dence to support visual examination or other methods 
of screening for oral cancer in the general population.17 
The sensitivity of visual examination of the mouth for 
detecting oral precancerous and cancerous lesions varies 
from 58% to 94% and the specificity from 76% to 98%. 
These figures may be even lower for areas affected by 
HPV related oropharyngeal cancer, such as the tonsil and 
base of tongue, which are less accessible. Randomised 
studies in areas of high incidence have suggested that 
opportunistic visual screening of high risk groups may 
reduce mortality.18 In special groups such as patients 
with Fanconi’s anaemia, who have a higher lifetime risk 
of developing head and neck cancer, it is recommended 
that everyone over the age of 10 is screened every four 
months.19
Box 3 | Investigations used for head and neck cancer
Imaging
Computed tomography scanning from the skull base to the diaphragm is the first line 
investigation to assess nodal metastasis and identify the primary tumour site and tumour size
Magnetic resonance imaging is indicated for:
•	Oral cavity and oropharyngeal tumours; it provides better information than because of 
the absence of interference from dental amalgam and the better delineation of soft tissue 
extension
•	Cases where extension through the laryngeal cartilage is suspected but cannot be 
conclusively determined on computed tomography
Ultrasound guided fine needle aspiration performed by experienced practitioners is 
highly accurate and used by some centres to diagnose nodal metastasis and determine its 
distribution14
Positron emission tomography-computed tomography scanning is used to investigate occult 
primary and distant metastases in some cases
Sentinel node biopsy is used to detect nodal metastases in cases with a high risk of occult 
metastasis. A radioactive tracer with blue dye is injected into the lesion, often a mouth 
cancer, and under general anaesthesia a Geiger counter locates the node with highest 
radioactivity, which is removed. If the node contains tumour, the patient undergoes neck 
dissection
Histological confirmation of diagnosis
Examination under anaesthetic and biopsy allows assessment of the size and extent of the 
primary tumour
Fine needle aspiration or core biopsy, often under ultrasound guidance, can provide 
cytological evidence of nodal metastasis14
Positron emission tomography-computed tomography scans showing: left, recurrence in neck 
(arrow) in a patient who had previously undergone a neck dissection and chemoradiotherapy; 
and right, 53 year old man with adenoid cystic carcinoma of the parotid gland showing spinal 
metastases in the fourth lumbar vertebra
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Can head and neck cancer be prevented?
Prevention of head and neck cancer is closely linked to the 
success of tobacco control programmes. After pooling more 
than 50 000 sets of individual level data from case-control 
studies, INHANCE estimated that quitting tobacco smoking 
for one to four years reduces the risk of developing head 
and neck cancer (0.70, 0.61 to 0.81 compared with current 
smoking), with further risk reduction at 20 years or more 
(0.23, 0.18 to 0.31), at which time risk is similar to that of 
never smokers.5 For alcohol use, a beneficial effect was seen 
only after 20 years or more of quitting (0.60, 0.40 to 0.89 
compared with current drinking).20
HPV related oropharygeal cancer may theoretically be 
prevented by vaccination against HPV-16, although no 
strong evidence is available to support this. Currently, most 
national HPV vaccination programmes include only girls, 
because several health economics assessments did not sup-
port the cost effectiveness of including boys.21 However the 
rapid increase in HPV related oropharygeal cancer has led 
some health professionals to call for a reassessment of the 
cost effectiveness of including boys in such programmes.4
Thanks to Olu Adesanya, University Hospitals Coventry and Warwickshire, for 
supplying the figures, and to Mr  and Mrs Culling for supplying the resources for 
patients and carers.
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ADDITIONAL EDUCATIONAL RESOURCES 
Resources for healthcare professionals
WHO. The global burden of disease: 2004 update. 2008. www.who.int/evidence/bod
National Cancer Comprehensive Network (www.nccn.org/index.asp)—Guidelines on 
treatment of cancers including head and neck in US 
Scottish Intercollegiate Guidelines Network. Diagnosis and management of head and 
neck cancer guidelines. Guideline no 90. 2006. www.sign.ac.uk/guidelines/fulltext/90/
index.html 
National Institute for Health and Clinical Excellence. Improving outcomes in head and neck 
cancers—the manual. 2004. http://guidance.nice.org.uk/csghn/guidance/pdf/English
Fanconi Anaemia Clinical Network. Clinical standards of care in the UK. www.fanconi.org.uk/
clinical-network/standards-of-care/
Resources for patients and carers
Cancer Research UK (www.cancerresearchuk.org)—National site that covers all cancers; very 
easy to navigate with lots of information
Macmillan (www.macmillan.org.uk)—National site that covers all cancers; easy to navigate; 
need to type larynx into the search engine
Merseyside Head and Neck Cancer Centre (www.headandneckcancer.co.uk)—Suitable for 
patients and carers in any part of the country, easy to navigate, very clear language and 
format
Get A-Head (http://www.getahead.org.uk)—Easy to navigate, suitable for patients and 
carers in any part of the country, very informative; click on “patient info” then “helpful 
information”
National Association of Laryngectomee Clubs (www.laryngectomy.org.uk)—Patient 
organised site with a wide selection of information for patients and professionals; hard 
copies are free on request
Guidelines and Audit Implementation Network (http://www.gain-ni.org)—Informal learning 
course of six modules 
TIPS FOR NON-SPECIALISTS
•	Refer any patient with hoarseness, stridor, swallowing 
problem, unilateral ear pain, lump in the neck, red or 
white patch or ulceration in the mouth, cranial nerve 
palsy, or orbital masses, to a specialist urgently
•	Patterns of presentation of head and neck cancer 
are changing, possibly because of a rise in human 
papillomavirus related cancers. Patients may present 
at younger age—30-50—with an isolated neck lump 
and may not give a history of smoking or heavy alcohol 
consumption
This week’s cover image of Henry 
reproduced with permission of the 
charity Saving Faces.
Henry underwent several 
operations culminating in the 
removal of all his right upper jaw 
and maxillary sinus for what was 
thought to be a benign tumour. 
In fact it was a malignant bone 
tumour (osteosarcoma). He sought 
treatment from lain Hutchison, 
chief executive of Saving Faces, 
but was advised that because 
of the position of the tumour 
an unacceptable amount of his 
face would need to be excised 
to achieve its total removal. The 
affected area was built up using 
rib to reconstruct the underlying 
facial architecture, latissimus dorsi 
muscle from the back to seal the 
space between the brain and the 
mouth, and skin from the back 
to replace lost skin. The tumour 
recurred five years later on the left 
side of his upper jaw, and Henry’s 
left upper jaw, sinus and nasal 
support were removed. No surgical 
reconstruction was carried out, but 
he wore a large denture (obturator) 
to fill the space.
